Don't Buy Intra-Cellular Therapies Without Checking Its Fundamentals!

Shares of Health Care sector company Intra-Cellular Therapies moved -0.4% today, and are now trading at a price of $64.17. The mid-cap stock's daily volume was 375,236 compared to its average volume of 894,263. The S&P 500 index returned a 0.0% performance.

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company is based in New York and has 561 full time employees. Its market capitalization is $6,175,598,592.

14 analysts are following Intra-Cellular Therapies and have set target prices ranging from $58.0 to $101.0 per share. On average, they have given the company a rating of buy. At today's prices, ITCI is trading -17.05% away from its average analyst target price of $77.36 per share.

Over the last year, ITCI's share price has increased by 22.0%, which represents a difference of 5.8% when compared to the S&P 500. The stock's 52 week high is $67.05 per share whereas its 52 week low is $42.01. Intra-Cellular Therapies has averaged free cash flows of $-194998002.8 over the last 6 years, with a mean growth rate of -11.8%. It is unlikely that the stock can sustain its current performance trend for the long term when the underlying business is experiencing such poor cash flows.

Date Reported Cash Flow from Operations ($ k) Capital expenditures ($ k) Free Cash Flow ($ k) YoY Growth (%)
2023 -161,331 240 -161,571 40.37
2022 -270,186 778 -270,964 -4.27
2021 -259,544 325 -259,869 -12.82
2020 -230,073 267 -230,340 -79.0
2019 -127,983 700 -128,684 -8.54
2018 -118,169 391 -118,560
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS